Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14234095 | 0.89 | ALDH1A1 (0.62) | RAB9ANPC1TP53SMN1; SMN2NPSR1 | |
| SCHEMBL10272898 | 0.89 | RAB9A (0.65) | RAB9ANPC1TP53SMN1; SMN2NPSR1 | |
| SCHEMBL19070392 | 0.87 | ALDH1A1 (0.62) | RAB9ANPC1TP53SMN1; SMN2NPSR1 | |
| SCHEMBL7901273 | 0.86 | SMN1; SMN2 (0.65) | RAB9ANPC1TP53SMN1; SMN2L3MBTL1 | |
| SCHEMBL4480468 | 0.86 | SMN1; SMN2 (0.61) | RAB9ANPC1TP53SMN1; SMN2L3MBTL1 | |
| SCHEMBL9472983 | 0.86 | RAB9A (0.61) | RAB9ANPC1TP53SMN1; SMN2NPSR1 | |
| SCHEMBL17078828 | 0.85 | ALDH1A1 (0.61) | RAB9ANPC1TP53SMN1; SMN2NPSR1 | |
| SCHEMBL18901286 | 0.85 | ALDH1A1 (0.61) | RAB9ANPC1TP53SMN1; SMN2NPSR1 | |
| SCHEMBL4486004 | 0.85 | KMT2A (0.66) | RAB9ANPC1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL10174738 | 0.85 | KMT2A (0.66) | RAB9ANPC1TP53SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019154366-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏奥赛康药业有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100056505-A1 | Substituted Pyrazalones | BIOGEN IDEC MA INC. | 2010-03-04 | — | — | US | disclosed |
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2009-10-29 | — | — | US | disclosed |
| WO-2009077186-A1 | NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESLLSCHAFT (DE) | 2009-06-25 | — | — | WO | disclosed |
| US-20090143412-A1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER HEALTHCARE LLC (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-7442703-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-7429584-B2 | Furo[2.3-b]pyridine derivatives for the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-7384948-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | RAB9A 559/4885NPC1 1955/4885TP53 4768/4885 |
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | RAB9A 4690/4885NPC1 4133/4885TP53 2468/4885 |
| US-20100056505-A1 | Substituted Pyrazalones | ACVR1, ACVRL1, TGFBR1 | RAB9A 2969/4885NPC1 4203/4885TP53 1467/4885 |
| US-20090143412-A1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | NCOR1, NR3C1, NR3C2 | RAB9A 4463/4885NPC1 424/4885TP53 794/4885 |
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | RAB9A 1186/4885NPC1 631/4885TP53 1860/4885 |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | RAB9A 1165/4885NPC1 2846/4885TP53 1917/4885 |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | RAB9A 4606/4885NPC1 3356/4885TP53 3052/4885 |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | RAB9A 1523/4885NPC1 2223/4885TP53 2260/4885 |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | RAB9A 2000/4885NPC1 709/4885TP53 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.